Literature DB >> 20415539

Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus.

Jonathan A McCullers1, Lee-Ann Van De Velde, Kim J Allison, Kristen C Branum, Richard J Webby, Patricia M Flynn.   

Abstract

BACKGROUND. The world is facing a novel H1N1 influenza pandemic. A pandemic scare with a similar influenza virus in 1976 resulted in the vaccination of nearly 45 million persons. We hypothesized that prior receipt of the 1976 "swine flu" vaccine would enhance immune responses to the 2009 novel H1N1 influenza strain. METHODS. A prospective, volunteer sample of employees aged > or = 55 years at a children's cancer hospital in August 2009 was assessed for antibody responses to the 2009 pandemic H1N1 influenza virus and the 2008-2009 seasonal H1N1 influenza virus. RESULTS. Antibody responses by hemagglutination-inhibition assay were high against both the seasonal influenza virus (89.7% had a titer considered seroprotective) and pandemic H1N1 influenza virus (88.8% had a seroprotective titer). These antibodies were effective at neutralizing the seasonal H1N1 influenza virus in 68.1% of participants (titer > or = 40), but only 18.1% had detectable neutralizing titers against the pandemic H1N1 influenza virus. Of 116 participants, 46 (39.7%) received the 1976 "swine flu" vaccine. Receipt of this vaccine significantly enhanced neutralization responses; 8 (17.4%) of 46 vaccine recipients had titers > or = 160, compared with only 3 (4.3%) of 70 who did not receive the vaccine (P = .018 by chi(2) test). CONCLUSIONS. In this cohort, persons aged > or = 55 years had evidence of robust immunity to the 2008-2009 seasonal H1N1 influenza virus. These antibodies were cross-reactive but nonneutralizing against the 2009 pandemic H1N1 influenza strain. Receipt of a vaccine to a related virus significantly enhanced the neutralization capacity of these responses, suggesting homologous vaccination against the 2009 pandemic H1N1 influenza virus would have a similar effect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20415539      PMCID: PMC2946351          DOI: 10.1086/652441

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

1.  Increased influenza vaccination of healthcare workers at a pediatric cancer hospital: results of a comprehensive influenza vaccination campaign.

Authors:  Jonathan A McCullers; Kathleen M Speck; Bonnie F Williams; Hua Liang; Joseph Mirro
Journal:  Infect Control Hosp Epidemiol       Date:  2006-01-06       Impact factor: 3.254

2.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

Authors:  Anthony E Fiore; David K Shay; Karen Broder; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy J Cox
Journal:  MMWR Recomm Rep       Date:  2009-07-31

3.  Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets.

Authors:  Victor C Huber; Jonathan A McCullers
Journal:  J Infect Dis       Date:  2006-01-27       Impact factor: 5.226

4.  The impact of influenza epidemics on hospitalizations.

Authors:  L Simonsen; K Fukuda; L B Schonberger; N J Cox
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

5.  A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.

Authors:  Victor C Huber; Paul G Thomas; Jonathan A McCullers
Journal:  Vaccine       Date:  2009-01-07       Impact factor: 3.641

Review 6.  Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans.

Authors:  J S Malik Peiris; Leo L M Poon; Yi Guan
Journal:  J Clin Virol       Date:  2009-06-11       Impact factor: 3.168

7.  Multiple genotypes of influenza B virus circulated between 1979 and 2003.

Authors:  Jonathan A McCullers; Takehiko Saito; Amy R Iverson
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

8.  Reflections on the 1976 swine flu vaccination program.

Authors:  David J Sencer; J Donald Millar
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

9.  Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza?

Authors:  Tom Reichert; Gerardo Chowell; Hiroshi Nishiura; Ronald A Christensen; Jonathan A McCullers
Journal:  BMC Infect Dis       Date:  2010-01-07       Impact factor: 3.090

10.  Swine influenza a outbreak, Fort Dix, New Jersey, 1976.

Authors:  Joel C Gaydos; Franklin H Top; Richard A Hodder; Philip K Russell
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

View more
  37 in total

1.  Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets.

Authors:  Ji-Young Min; Grace L Chen; Celia Santos; Elaine W Lamirande; Yumiko Matsuoka; Kanta Subbarao
Journal:  Virology       Date:  2010-12-05       Impact factor: 3.616

2.  Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus.

Authors:  Gillian M Air; Jingqi Feng; Tao Chen; Michelle L Joachims; Judith A James; Linda F Thompson
Journal:  J Clin Immunol       Date:  2011-07-06       Impact factor: 8.317

3.  Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children.

Authors:  Nitin Verma; Milena Dimitrova; Donald M Carter; Corey J Crevar; Ted M Ross; Hana Golding; Surender Khurana
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 4.  Pandemic influenza: certain uncertainties.

Authors:  David M Morens; Jeffery K Taubenberger
Journal:  Rev Med Virol       Date:  2011-06-27       Impact factor: 6.989

Review 5.  Seroprevalence to influenza A(H1N1) 2009 virus--where are we?

Authors:  Eeva Broberg; Angus Nicoll; Andrew Amato-Gauci
Journal:  Clin Vaccine Immunol       Date:  2011-06-08

6.  Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.

Authors:  Rory D de Vries; Arwen F Altenburg; Nella J Nieuwkoop; Erwin de Bruin; Stella E van Trierum; Mark R Pronk; Mart M Lamers; Mathilde Richard; David F Nieuwenhuijse; Marion P G Koopmans; Joost H C M Kreijtz; Ron A M Fouchier; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2018-07-13       Impact factor: 5.226

7.  Swine outbreak of pandemic influenza A virus on a Canadian research farm supports human-to-swine transmission.

Authors:  Sarah E Forgie; Julia Keenliside; Craig Wilkinson; Richard Webby; Patricia Lu; Ole Sorensen; Kevin Fonseca; Subrata Barman; Adam Rubrum; Evelyn Stigger; Thomas J Marrie; Frank Marshall; Donald W Spady; Jia Hu; Mark Loeb; Margaret L Russell; Lorne A Babiuk
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079

8.  Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection.

Authors:  Hana Hakim; Kim J Allison; Lee-Ann Van de Velde; Li Tang; Yilun Sun; Patricia M Flynn; Jonathan A McCullers
Journal:  Vaccine       Date:  2016-04-26       Impact factor: 3.641

9.  A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.

Authors:  Joost H C M Kreijtz; Lidewij C M Wiersma; Heidi L M De Gruyter; Stella E Vogelzang-van Trierum; Geert van Amerongen; Koert J Stittelaar; Ron A M Fouchier; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2014-09-22       Impact factor: 5.226

10.  Humoral immune responses during asthma and influenza co-morbidity in mice.

Authors:  Laura A Doorley; Kim S LeMessurier; Amy R Iverson; Maneesha Palipane; Amali E Samarasinghe
Journal:  Immunobiology       Date:  2017-09-07       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.